Welcome to our dedicated page for Lineage Cell Therapeutics news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell Therapeutics stock.
Lineage Cell Therapeutics, Inc. develops allogeneic, or “off-the-shelf,” cell therapies for serious medical conditions using its AlloSCOPE cell differentiation and expansion platform. Its pipeline includes OpRegen, also known as RG6501, for geographic atrophy secondary to age-related macular degeneration; OPC1 for spinal cord injury; ReSonance, or ANP1, for hearing loss; and COR1 for corneal endothelial disease.
Recurring company news covers clinical data presentations, preclinical program launches, manufacturing and platform updates, research collaborations, milestone activity, financial results, business updates, and scientific governance. Updates frequently connect Lineage’s cell transplant programs with ophthalmology, neurology, auditory disease, and other non-oncology therapeutic areas.
Lineage Cell Therapeutics, Inc. presented 24-month visual acuity results of OpRegen (RG6501) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at the 2024 Retinal Cell & Gene Therapy Innovation Summit. The data showed BCVA gains of +5.5 letters at 24 months in Cohort 4 patients, with additional gains observed in patients with extensive OpRegen bleb coverage. The study suggested that OpRegen may counteract RPE cell dysfunction and loss in GA by supporting remaining retinal cells, with effects lasting at least 2 years post-administration.
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) will announce its first quarter 2024 financial results on May 9, 2024. The company, focused on developing allogeneic cell therapies, will host a conference call to discuss the results and provide a business update.
Lineage Cell Therapeutics, Inc. (LCTX) received an Education Conference II Grant from the California Institute for Regenerative Medicine (CIRM) to support the 2nd Annual Spinal Cord Injury Investor Symposium. The symposium aims to accelerate development in spinal cord injury research and treatments by bringing together stakeholders in the field. It will focus on discussing current and future treatment alternatives, raising investor awareness, and broadening investment into spinal cord injury. The event will feature speakers from various organizations and will take place on June 26 and 27, 2024, in La Jolla, CA.
Lineage Cell Therapeutics, Inc. announces the passing of its Chairman, Mr. Alfred D. Kingsley, and appoints Michael H. Mulroy, J.D., as the new Chairman of the Board of Directors. Mr. Kingsley's significant contributions to the company are acknowledged, and Mr. Mulroy brings extensive experience in biotech and biopharma to his new role.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.